Radafaxine

Antidepressant

Template: Infobox chemical / molecular formula search available

Radafaxin is a selective norepinephrine - dopamine reuptake inhibitor ( NDRI ), which was originally developed by GlaxoSmithKline for the treatment of Restless Legs Syndrome. However, the development was stopped in 2006 due to poor test results.

Chemistry and stereoisomerism

Radafaxin is enantiomerically pure and can be considered a derivative of the drug bupropion ( racemate) are considered. The effects of Radafaxin in humans are similar to those of bupropion.

Pharmacological properties

Radafaxin blocks the reuptake of dopamine with 70 % of the efficiency of bupropion and norepinephrine with 392 % efficiency.

The effectiveness of Radafaxin used to treat depression, obesity and neuropathic pain has been studied in clinical trials. This had turned out that Radafaxin unlike bupropion is better suited for the treatment of pain and fatigue, which is probably related to the stronger reuptake inhibition of the neurotransmitter norepinephrine.

Similar Bupropion also Radafaxin to have a low abuse potential.